StockData
Intellia Therapeutics, Inc. logo

Intellia Therapeutics, Inc. (NTLA) stock

NTLANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/307% above fair value
$9.77−0.01 (-0.10%)

Close on Nov 18, 2026Market cap $1.37BP/E –Yield –

Intellia Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Intellia Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $59.51M, up 12.6% year over year. For fiscal 2025 it was $67.67M, up 16.9% from the year before. The highest annual figure on record is $67.67M in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$67.67M+16.9%
FY2024Dec 31, 2024$57.88M+59.6%
FY2023Dec 31, 2023$36.28M-30.4%
FY2022Dec 31, 2022$52.12M+57.7%
FY2021Dec 31, 2021$33.05M-43.0%
FY2020Dec 31, 2020$57.99M+34.5%
FY2019Dec 31, 2019$43.10M+41.6%
FY2018Dec 31, 2018$30.43M+16.5%
FY2017Dec 31, 2017$26.12M+58.5%
FY2016Dec 31, 2016$16.48M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$7.66M-46.2%
Q1 FY2026Mar 31, 2026$15.05M-9.5%
Q4 FY2025Dec 31, 2025$23.02M+78.8%
Q3 FY2025Sep 30, 2025$13.78M+51.3%
Q2 FY2025Jun 30, 2025$14.25M+104.8%
Q1 FY2025Mar 31, 2025$16.63M-42.5%
Q4 FY2024Dec 31, 2024$12.87M+7.4%
Q3 FY2024Sep 30, 2024$9.11M-33.0%
Q2 FY2024Jun 30, 2024$6.96M-44.8%
Q1 FY2024Mar 31, 2024$28.94M+113.2%
Q3 FY2023Sep 30, 2023$11.99M-9.6%
Q2 FY2023Jun 30, 2023$13.59M-3.1%
Q1 FY2023Mar 31, 2023$12.61M+12.0%
Q4 FY2022Dec 31, 2022$13.57M+5.6%
Q3 FY2022Sep 30, 2022$13.27M+84.1%
Q2 FY2022Jun 30, 2022$14.03M+114.2%
Q1 FY2022Mar 31, 2022$11.25M+74.6%
Q4 FY2021Dec 31, 2021$12.85M+94.9%
Q3 FY2021Sep 30, 2021$7.20M-67.6%
Q2 FY2021Jun 30, 2021$6.55M-59.7%
Q1 FY2021Mar 31, 2021$6.45M-50.1%
Q4 FY2020Dec 31, 2020$6.60M-39.7%
Q3 FY2020Sep 30, 2020$22.22M+109.3%
Q2 FY2020Jun 30, 2020$16.26M+46.3%
Q1 FY2020Mar 31, 2020$12.92M+23.8%
Q4 FY2019Dec 31, 2019$10.94M+38.8%
Q3 FY2019Sep 30, 2019$10.62M+43.3%
Q2 FY2019Jun 30, 2019$11.12M+44.8%
Q1 FY2019Mar 31, 2019$10.43M+39.7%
Q4 FY2018Dec 31, 2018$7.88M+18.2%
Q3 FY2018Sep 30, 2018$7.41M+1.2%
Q2 FY2018Jun 30, 2018$7.68M+29.7%
Q1 FY2018Mar 31, 2018$7.47M+20.2%
Q4 FY2017Dec 31, 2017$6.67M–
Q3 FY2017Sep 30, 2017$7.32M–
Q2 FY2017Jun 30, 2017$5.92M–
Q1 FY2017Mar 31, 2017$6.22M–

More Intellia Therapeutics figures

See a number that looks wrong?